Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.54 |
| ▸ | BRD2 | P25440 | 5/20 | 0.53 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14756943 | 0.85 | BRD4 (0.58) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL16774314 | 0.85 | BRD4 (0.58) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL15985177 | 0.84 | BRD4 (0.68) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL16619166 | 0.82 | BRD4 (0.53) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL16619145 | 0.81 | BRD4 (0.54) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL16618707 | 0.81 | CYP3A4 (0.59) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL16618982 | 0.80 | BRD4 (0.65) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL13732483 | 0.79 | BRD4 (0.56) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL18249908 | 0.79 | BRD4 (0.56) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL17967393 | 0.79 | BRD4 (0.53) | BRD4BRD2BRD3CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015049629-A1 | IMIDAZOQUINOLINE COMPOUNDS AS BROMODOMAIN INHIBITORS | Piramal Enterprises Limited (IN) | 2015-04-09 | — | — | WO | disclosed |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013033269-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | BRD4 2/4885BRD2 5/4885BRD3 6/4885 |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | BRD4 2/4885BRD2 5/4885BRD3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.